Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887598 | 1.00 | P2RX7 (0.59) | P2RX7CTSKCTSSCTSLCTSB | |
| SCHEMBL19485480 | 0.93 | CTSK (0.62) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL9219338 | 0.93 | CTSK (0.62) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL3439255 | 0.91 | CTSS (0.62) | P2RX7CTSKCTSSCTSLCTSB | |
| SCHEMBL5887477 | 0.91 | CTSS (0.62) | P2RX7CTSKCTSSCTSLCTSB | |
| SCHEMBL9995844 | 0.91 | CTSK (0.60) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL2058584 | 0.91 | CTSK (0.60) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL15018841 | 0.91 | CTSK (0.60) | CTSKCTSSCTSLCTSBALDH1A1 | |
| Water SCHEMBL15019511 | 0.89 | CTSS (0.62) | CTSKCTSSCTSLCTSBALDH1A1 | |
| Water SCHEMBL15019510 | 0.89 | CTSS (0.62) | CTSKCTSSCTSLCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | P2RX7 4516/4885CTSK 2430/4885CTSS 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.